# Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

> **NCT00202020** · PHASE3 · COMPLETED · sponsor: **Otsuka Beijing Research Institute** · enrollment: 720 (—)

## Conditions studied

- Cerebral Infarction

## Interventions

- **DRUG:** Cilostazol 200mg/day Oral
- **DRUG:** Aspirin 100mg/day Oral

## Key facts

- **NCT ID:** NCT00202020
- **Lead sponsor:** Otsuka Beijing Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 720 (—)
- **Last updated:** 2006-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202020, "Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00202020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*